Meeting
2019 ASCO Annual Meeting
Pharmacodynamic effect of IMCgp100 (TCR–CD3 bispecific) on peripheral cytokines and association with overall survival in patients with advanced melanoma.
Authors
Mark R. Middleton
Churchill Hospital, Oxford, United Kingdom
Mark R. Middleton , Neil Matthew Steven , TR Jeffry Evans , Jeffrey R. Infante , Omid Hamid , Alexander Noor Shoushtari , Philippa Gail Corrie , Alan Anthoney , Avinash Gupta , Victoria K Woodcock , Cheryl McAlpine , Mario Sznol
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT01211262
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9523)
DOI
10.1200/JCO.2019.37.15_suppl.9523
Abstract #
9523
Poster Bd #
94
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in patients (pts) with previously treated (2L+) metastatic uveal melanoma (mUM).
First Author: Richard D. Carvajal
Poster
2019 ASCO Annual Meeting
Relationship between clinical efficacy and AEs of IMCgp100, a novel bispecific TCR–anti-CD3, in patients with advanced melanoma.
First Author: Mark R. Middleton
Poster
2017 ASCO Annual Meeting
Intra-patient escalation dosing strategy with IMCgp100 results in mitigation of T-cell based toxicity and preliminary efficacy in advanced uveal melanoma.
First Author: Takami Sato
Poster
2016 ASCO Annual Meeting
Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma.
First Author: Mark R. Middleton